- Global Pharma News & Resources

Original-Research: Expedeon AG (von GBC AG)

Original-Research: Expedeon AG - von GBC AG Einstufung von GBC AG zu Expedeon AG Unternehmen: Expedeon AG ISIN: DE000A2YN801 Anlass der Studie: Research Comment Empfehlung: BUY Kursziel: 3.20 Euro Kursziel auf Sicht von: 31/12/2020 Letzte Ratingänderung: Analyst: Cosmin Filker, Marcel Goldmann Sale of the immunology and proteomics divisions will net EUR120 million (EUR2.29 per share), DNA business is to be expanded On 11/11/2019, Expedeon AG reached an agreement with antibody online distributor Abcam plc for the planned sale of the immunology and proteomics businesses. If the deal is approved at the extraordinary general meeting set for 19/12/2019, the transaction is expected to be closed on 01/01/2020. According to the agreement, a total purchase price of EUR120 million (in cash) is to be paid for the purchase of the two divisions, with EUR105.6 million payable immediately and EUR14.4 million paid over a two-year period. The business segments about to be sold were acquired by Expedeon AG in recent financial years as part of intensive M&A activities. Starting with the purchase of the now eponymous proteomics specialist Expedeon in 2016, the electrophoresis equipment provider C.B.S. Scientific was purchased in late 2016. These acquisitions were followed by the purchase of protein measurement companies Innova Biosciences (2017) and TGR Biosciences (2018). The total purchase price for these four companies is EUR39.8 million, i.e. appreciably less than the sale price of around EUR120 million that will now be realised. Expedeon AG's current market capitalisation of EUR83.2 million would also be significantly exceeded with the purchase price. According to our findings, the divisions and products to be sold account for around 90% of Expedeon's annual sales and should make a sharply positive earnings contribution. With annual sales of these products expected to be around EUR14.4 million for 2019, this would represent a purchase price multiple exceeding 8. After the planned deal is finalised, the product area of the 'genomics' segment is to remain in Expedeon AG (the name of which is proposed to be changed to '4BaseBio AG' at the general meeting) with the key products TruePrimeTM, SunScript(R) and with products of the electrophoresis sector of the former C.B.S. Scientific. The operating figures for the coming financial year would also be marked by the loss of the major part of the sales proceeds and earnings contribution. In 2020, the company should post only around 10% of the current revenue level, or around EUR1.6 - 2.0 million. From the current standpoint, however, we cannot yet estimate the actual impact, and for this reason we are not changing our previous forecasts for the time being (see Research report dated 07/10/2019). The company specifically expects that overall 38% of the operating assets will not be sold. US subsidiary Expedeon Inc. is not to be included in the sale assets, but is to be transferred prior to the sale from Expedeon Holdings Ltd. to Expedeon AG. According to the company, the future focus will be on the proprietary technology TruePrimeTM, and specifically on the expansion of GMP-certified production of DNA. This is to be supplied to pharma and biotech companies which need large quantities of good quality DNA for the production of gene therapies or gene vaccines. To complement this, additional products and technologies are to be acquired as part of a buy&build strategy. Expedeon's management has, with its previous M&A successes, delivered proof of concept for the success of this strategy. According to the company's management board (company presentation), up to EUR13.5 million in revenues are expected to be generated by 2022 in the gene therapy and diagnostic business areas. If the deal is successfully completed, as we assume it will be, Expedeon AG would have cash and cash equivalents of EUR120 million (incl. cash inflow in the next two years), resulting in significant financial leeway. This would be equivalent to liquidity of EUR2.29 per share, which in our view now represents the valuation floor for the Expedeon share. Until we can concretely estimate the remaining business, we also confirm our previous price target of EUR3.20 per share. We continue to assign it a BUY rating. Die vollständige Analyse können Sie hier downloaden: Kontakt für Rückfragen Jörg Grunwald Vorstand GBC AG Halderstraße 27 86150 Augsburg 0821 / 241133 0 ++++++++++++++++ Offenlegung möglicher Interessenskonflikte nach § 85 WpHG und Art. 20 MAR. Beim oben analysierten Unternehmen ist folgender möglicher Interessenkonflikt gegeben: (4,5a,7,10,11); Einen Katalog möglicher Interessenkonflikte finden Sie unter: +++++++++++++++ Date of completion/Date of first distribution (german version): 13/11/19 (1:56 pm) / 14/11/19 (9:30 am) Date of completion/Date of first distribution (english version): 03/12/19 (09:47 am) / 03/12/19 (11:00 am) -------------------übermittelt durch die EQS Group AG.------------------- Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.

Editor Details

Last Updated: 03-Dec-2019